Atossa Therapeutics, Inc.’s Post

AbbVie and Landos Biopharma, Inc. Biopharma ("Landos") today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair. "With this acquisition, we aim to advance the clinical development of NX-13, a differentiated, first-in-class, oral asset with the potential to make a difference in the lives of people living with ulcerative colitis and Crohn's disease," said Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie. "This announcement is a testament to Landos' talented team and their commitment to our mission of creating oral treatments that can address a therapeutic gap," said Gregory Oakes, president and chief executive officer, Landos. "NX-13 and its bimodal MOA have the potential to provide a novel approach to the treatment of ulcerative colitis and Crohn's disease. With AbbVie's therapeutic area leadership and expertise in global development, they are the right company to further advance NX-13." Under the terms of the agreement, AbbVie will acquire Landos at a price of $20.42 per share in cash upon closing, or approximately $137.5 million in the aggregate, plus one non-tradable contingent value right per share with a value of up to $11.14 per share, or approximately an additional $75 million in the aggregate, subject to the achievement of a clinical development milestone. The proposed transaction is expected to close in the second calendar quarter of 2024, subject to customary closing conditions, including approval by Landos' stockholders. #immunology #autoimmunediseases #ulcerativecolitis #crohnsdisease  #acquisition #Landos #AbbVie #AbbVieImmunology  👉 AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases - Mar 25, 2024

🌐 Gilead Sciences: Navigating the Pharma Landscape with Strategic Acquisitions and Oncology Focus 🌐 Join the discussion on Gilead Sciences' current standing in the pharmaceutical industry. Delve into the impact of recent acquisitions, the company's pivot towards oncology, and its proactive measures to address revenue challenges. Discover why Gilead is emerging as a compelling player in the ever-evolving pharma landscape. Read more: https://lnkd.in/dTf5Mdrb #GileadSciences #Pharmaceuticals #InvestmentOpportunity

#Antibody-drug conjugates (#ADCs) dominated 2023 dealmaking, with some of the largest drugmakers – Pfizer, Merck & Co., AbbVie, and Bristol Myers Squibb – inking pacts worth billions. Now Roche, which markets two of the earliest approved ADCs, is investing in the space once again through a partnership with MediLink announced Tuesday that could be worth close to $1 billion. Roche is gaining exclusive global rights to YL211, an ADC targeting c-Met to treat solid tumours. The firm’s China Innovation Center will partner with MediLink Therapeutics to start a Phase I trial of YL211. MediLink Therapeutics will receive $50 million, comprising an upfront payment and near-term milestones, and is eligible for additional development, regulatory, and commercial milestones for a total deal value near $1 billion, plus tiered royalties." https://lnkd.in/dhMRePMC. #carletto #linkedin #vita #salute #sanita #donna #uomo #pharma

Some of the latest Life Science News / Updates: ➡ Veeda Clinical Research Limited acquires European CRO - Heads ➡ Novo Nordisk to acquire heart-disease focused Cardior Pharmaceuticals in deal worth $1.1 billion ➡ Gilead Sciences completes acquisition of CymaBay Therapeutics for approximately $4.3 billion ➡ AbbVie to acquire Landos Biopharma, Inc. further strengthening its portfolio in Inflammatory and Autoimmune diseases ➡ Avenzo Therapeutics raises $150M in Series A1- financing ➡ Nocion Therapeutics, Inc. has raised $62 million series B, bringing the company's total raised to $122 million since 2018 ➡ FogPharma has raised $145 million in a series E ➡ BlossomHill Therapeutics, Inc. has raised $100 million in a series B, bringing the company’s total fundraising to $173 million

The 15 biggest biopharma deals of 2023 were worth ~$130 billion. Here's a look at 3 key trends behind them: 1. Pfizer's $43B acquisition of Seagen was the largest, coming in at ~5 times the average deal size of $8B. Bristol Myers Squibb did the most deals (3) in the top 15, followed by Roche (2) and AbbVie (2). 2. Deal premiums varied widely: For the 13/15 targets that were publicly traded, the average deal premium was 86%. The biggest premium was paid in Sanofi's acquisition of Provention Bio, representing a ~270% premium to the share price prior to the deal. 3. Oncology (unsurprisingly) had a disproportionate amount of activity. While it accounted for ~25% of deals, it represented ~50% of deal value. Oncology was followed by Central Nervous System (3 deals), and Immunology (3 deals) as the most active therapeutic areas. With capital markets recovering, 2024 is shaping up to be a busy year likely to bring back dynamism to a dealmaking lull in the past two years.

Merck overtakes Pfizer as the top pharma company in 2023 thanks to consistent growth in its oncology and vaccine portfolios. In the longer run, Merck must contend with a looming patent expiry in 2028 for Keytruda, one of the best-selling oncology drugs in history but this challenge is also an opportunity to further diversify its product pipeline. #Pharmaceuticals #Oncology #Merck #Keytruda

AbbVie Inc (NYSE:ABBV)'s approximately $137.5 million acquisition of Landos Biopharma is a strategic move by the pharmaceutical research and development firm which has reiterated the potential of novel innovations with high-growth prospects in the small-cap #biotech sector. AbbVie, best known for producing rheumatoid arthritis and Crohn's Disease medication Humira, on Monday announced the deal which will bolster its portfolio of drug candidates for inflammatory and autoimmune diseases.   Landos Biopharma’s lead clinical asset is NX-13, an oral NLRX1 agonist that is in Phase 2 trials for the treatment of the inflammatory bowel disease ulcerative colitis.  For investors focused on small-cap opportunities in the biotech sector, the acquisition has underscored the allure and potential of up-and-coming biotech firms with promising therapeutic candidates. More at #Proactive #ProactiveInvestors #NASDAQ #IMUX http://ow.ly/IVw7105nqFO

Many pharma manufacturers of oncology blockbusters are facing patent cliffs and exposures due to loss of exclusivity. 🎯 As such, many are looking to other modalities and acquisition targets for late-stage assets and platforms to support drug discovery efforts, and to help slow the looming revenue bleed as part of their strategic direction. 🔬 Below, for instance, it appears that with only two other radiopharmaceutical interventions on market, BMS has identified an area of significant opportunity, as they acquire RayzeBio and associated platforms. 🤔 Curious to better understand how the market is poised to manage the forthcoming challenges of LOE? 🔎 Our team of Professional Life Science Associates utilizes sophisticated monitoring and surveillance tools to track, from local to global scale, movements and shifts in these key therapeutic classes. We back this knowledge with powerful primary intelligence and tap from a vast and established network of practitioners and KOLs to help your teams understand the implications of your near-term, mid-term, and strategic business imperatives. Contact us today to learn more about our capabilities to support your developmental and commercial Oncology programs. 🖥 Find us here ----> https://lnkd.in/emircSqg #BMS #BristolMyersSquibb #RayzeBio #BioTherapeutics #Oncology #Cancer #Radiopharmaceuticals #TargetedTherapy #Tumors #RadiationTherapy #Innovation #Pharma #Healthcare

Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, LSTA1, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate solid tumors more effectively. Based on Lisata’s CendR Platform® Technology, Lisata has already established noteworthy commercial and R&D partnerships. The Company expects to announce numerous clinical study and business milestones over the next two years and has projected that its current business and development plan is funded with available capital through these milestones and into early 2026. Meet Lisata Therapeutics, Inc. @ #Sachs_OIF More Info @ https://lnkd.in/djZps36w #OncologyInnovation #CancerResearch #BiotechInvesting #PharmaTrends #HealthcareInnovation #OncologyForum #CancerTherapyAdvancements #BiopharmaDeals #SachsForum #ASCO2024 "

In first biotech IPO of the year, CG Oncology overshoots estimates by bringing in $380M >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #competitivemarketing #biotech